In an interview with Pharmacy Times, Thomas Hope, MD, explains how earlier consideration of peptide receptor radionuclide therapy in neuroendocrine tumors makes treatment scheduling and continuity of care essential opportunities for pharmacists.
|Articles|March 8, 2022
Daily OTC Pearl: OTC Severe Sinus Medication
Author(s)Saro Arakelians, PharmD
Advertisement
OTC/Lifestyle Pearl of the Day: OTC Severe Sinus Medication
Indication: OTC severe sinus medications offer relief to sinus headaches, help to loosen phlegm, reduces sinus pressure and chest congestions, and temporarily reduces fever.
Insight:
- Warning: This product contains acetaminophen, which can affect the liver. Do not take other products that have acetaminophen in them.
- Maximum acetaminophen consumption: 4000 mg per day.
- Directions: 2 caplets every 4 hours.
- Do not take more than 10 caplets in 24 hours.
- For children under 12, ask a physician.
- Adverse effects: Dizziness, nervousness, redness, and swelling.
Sources:
Advertisement
Related to this article
From survodutide titration to oral PCSK9 adherence and HF care models, AHA 2026 experts pointed to pharmacists as key to putting new data into practice.
Durvalumab plus enfortumab vedotin reduced the risk of an event or death compared with radical cystectomy alone.
Christie Ballantyne, MD, says high extension enrollment and a single 20-mg daily dose are encouraging signs for patient adherence to oral enlicitide.
An ASRA-recognized quality improvement project draws attention to injectate reproducibility, offering a starting point for examining medication preparation and pharmacists’ role in safer pain procedures.
A meta-analysis presented at IDWeek 2026 found responses were stronger after chemotherapy but waned within a year, supporting a 2-dose strategy.
How should a factor XIa inhibitor be incorporated into secondary stroke prevention?
Inconsistent state immunization laws complicate pharmacy operations and limit patient access.
Advertisement
Advertisement
Trending on Pharmacy Times
1
From Recognition to Prior Authorization: ATTR-CM Diagnosis Gaps
2
AHA 2026: Pharmacists at the Center of Cardiometabolic Care
3
Pneumococcal Vaccines Show Moderate Immunogenicity, Strong Safety in Children With Cancer
4
FDA Approves Perioperative Durvalumab Plus Enfortumab Vedotin-ejfv for MIBC
5